(Q46548031)

23 December 2017

title

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging (English)

1 reference

23 December 2017

author name string

Douglas R Jeffery

1

1 reference

23 December 2017

Neraj Chepuri

2

1 reference

23 December 2017

David Durden

3

1 reference

23 December 2017

Jonathon Burdette

4

1 reference

23 December 2017

publication date

1 June 2005

1 reference

23 December 2017

Multiple Sclerosis Journal

published in

1 reference

23 December 2017

volume

11

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

296-301

1 reference

23 December 2017

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458505MS1154OA

10.1191/1352458505MS1154OA

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017